#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0113] In a further aspect, additional steps can be employed in combination with the activation methods and other steps disclosed above for adding a polyphosphazene of the present invention to the silicone-containing substrate.
1-1	0-1	[	_	_	
1-2	1-5	0113	_	_	
1-3	5-6	]	_	_	
1-4	7-9	In	_	_	
1-5	10-11	a	_	_	
1-6	12-19	further	_	_	
1-7	20-26	aspect	_	_	
1-8	26-27	,	_	_	
1-9	28-38	additional	_	_	
1-10	39-44	steps	_	_	
1-11	45-48	can	_	_	
1-12	49-51	be	_	_	
1-13	52-60	employed	_	_	
1-14	61-63	in	_	_	
1-15	64-75	combination	_	_	
1-16	76-80	with	_	_	
1-17	81-84	the	_	_	
1-18	85-95	activation	_	_	
1-19	96-103	methods	_	_	
1-20	104-107	and	_	_	
1-21	108-113	other	_	_	
1-22	114-119	steps	_	_	
1-23	120-129	disclosed	_	_	
1-24	130-135	above	_	_	
1-25	136-139	for	_	_	
1-26	140-146	adding	_	_	
1-27	147-148	a	_	_	
1-28	149-164	polyphosphazene	_	_	
1-29	165-167	of	_	_	
1-30	168-171	the	_	_	
1-31	172-179	present	_	_	
1-32	180-189	invention	_	_	
1-33	190-192	to	_	_	
1-34	193-196	the	_	_	
1-35	197-216	silicone-containing	_	_	
1-36	217-226	substrate	_	_	
1-37	226-227	.	_	_	

#Text=For example, the substrate can be treated with a cleaning agent, such as a chemical cleaning agent, or the substrate can be subjected to another treatment whereby contaminants on the surface or layer of the substrate are removed.
2-1	228-231	For	_	_	
2-2	232-239	example	_	_	
2-3	239-240	,	_	_	
2-4	241-244	the	_	_	
2-5	245-254	substrate	_	_	
2-6	255-258	can	_	_	
2-7	259-261	be	_	_	
2-8	262-269	treated	_	_	
2-9	270-274	with	_	_	
2-10	275-276	a	_	_	
2-11	277-285	cleaning	_	_	
2-12	286-291	agent	_	_	
2-13	291-292	,	_	_	
2-14	293-297	such	_	_	
2-15	298-300	as	_	_	
2-16	301-302	a	_	_	
2-17	303-311	chemical	_	_	
2-18	312-320	cleaning	_	_	
2-19	321-326	agent	_	_	
2-20	326-327	,	_	_	
2-21	328-330	or	_	_	
2-22	331-334	the	_	_	
2-23	335-344	substrate	_	_	
2-24	345-348	can	_	_	
2-25	349-351	be	_	_	
2-26	352-361	subjected	_	_	
2-27	362-364	to	_	_	
2-28	365-372	another	_	_	
2-29	373-382	treatment	_	_	
2-30	383-390	whereby	_	_	
2-31	391-403	contaminants	_	_	
2-32	404-406	on	_	_	
2-33	407-410	the	_	_	
2-34	411-418	surface	_	_	
2-35	419-421	or	_	_	
2-36	422-427	layer	_	_	
2-37	428-430	of	_	_	
2-38	431-434	the	_	_	
2-39	435-444	substrate	_	_	
2-40	445-448	are	_	_	
2-41	449-456	removed	_	_	
2-42	456-457	.	_	_	

#Text=These methods can comprise washing the substrate with a chemical agent such as an oxidizing agent, an acidic solution, an alkaline solution, or a reducing agent, that can possibly etch the silicone-containing substrate.
3-1	458-463	These	_	_	
3-2	464-471	methods	_	_	
3-3	472-475	can	_	_	
3-4	476-484	comprise	_	_	
3-5	485-492	washing	_	_	
3-6	493-496	the	_	_	
3-7	497-506	substrate	_	_	
3-8	507-511	with	_	_	
3-9	512-513	a	_	_	
3-10	514-522	chemical	_	_	
3-11	523-528	agent	_	_	
3-12	529-533	such	_	_	
3-13	534-536	as	_	_	
3-14	537-539	an	_	_	
3-15	540-549	oxidizing	_	_	
3-16	550-555	agent	_	_	
3-17	555-556	,	_	_	
3-18	557-559	an	_	_	
3-19	560-566	acidic	_	_	
3-20	567-575	solution	_	_	
3-21	575-576	,	_	_	
3-22	577-579	an	_	_	
3-23	580-588	alkaline	_	_	
3-24	589-597	solution	_	_	
3-25	597-598	,	_	_	
3-26	599-601	or	_	_	
3-27	602-603	a	_	_	
3-28	604-612	reducing	_	_	
3-29	613-618	agent	_	_	
3-30	618-619	,	_	_	
3-31	620-624	that	_	_	
3-32	625-628	can	_	_	
3-33	629-637	possibly	_	_	
3-34	638-642	etch	_	_	
3-35	643-646	the	_	_	
3-36	647-666	silicone-containing	_	_	
3-37	667-676	substrate	_	_	
3-38	676-677	.	_	_	

#Text=A separate drying step optionally can also be employed.
#Text=[0114] In further aspects, this disclosure provides methods for making a medical device comprising a polyorganosiloxane in combination with a polyphosphazene of the present invention.
4-1	678-679	A	_	_	
4-2	680-688	separate	_	_	
4-3	689-695	drying	_	_	
4-4	696-700	step	_	_	
4-5	701-711	optionally	_	_	
4-6	712-715	can	_	_	
4-7	716-720	also	_	_	
4-8	721-723	be	_	_	
4-9	724-732	employed	_	_	
4-10	732-733	.	_	_	
4-11	734-735	[	_	_	
4-12	735-739	0114	_	_	
4-13	739-740	]	_	_	
4-14	741-743	In	_	_	
4-15	744-751	further	_	_	
4-16	752-759	aspects	_	_	
4-17	759-760	,	_	_	
4-18	761-765	this	_	_	
4-19	766-776	disclosure	_	_	
4-20	777-785	provides	_	_	
4-21	786-793	methods	_	_	
4-22	794-797	for	_	_	
4-23	798-804	making	_	_	
4-24	805-806	a	_	_	
4-25	807-814	medical	_	_	
4-26	815-821	device	_	_	
4-27	822-832	comprising	_	_	
4-28	833-834	a	_	_	
4-29	835-853	polyorganosiloxane	_	_	
4-30	854-856	in	_	_	
4-31	857-868	combination	_	_	
4-32	869-873	with	_	_	
4-33	874-875	a	_	_	
4-34	876-891	polyphosphazene	_	_	
4-35	892-894	of	_	_	
4-36	895-898	the	_	_	
4-37	899-906	present	_	_	
4-38	907-916	invention	_	_	
4-39	916-917	.	_	_	

#Text=This disclosure also provides methods of imparting improving properties to the medical devices by, for example, reducing cell encrustation, reducing the severity of thrombosis, or improving the anti-rejection properties of the medical device.
5-1	918-922	This	_	_	
5-2	923-933	disclosure	_	_	
5-3	934-938	also	_	_	
5-4	939-947	provides	_	_	
5-5	948-955	methods	_	_	
5-6	956-958	of	_	_	
5-7	959-968	imparting	_	_	
5-8	969-978	improving	_	_	
5-9	979-989	properties	_	_	
5-10	990-992	to	_	_	
5-11	993-996	the	_	_	
5-12	997-1004	medical	_	_	
5-13	1005-1012	devices	_	_	
5-14	1013-1015	by	_	_	
5-15	1015-1016	,	_	_	
5-16	1017-1020	for	_	_	
5-17	1021-1028	example	_	_	
5-18	1028-1029	,	_	_	
5-19	1030-1038	reducing	_	_	
5-20	1039-1043	cell	_	_	
5-21	1044-1056	encrustation	_	_	
5-22	1056-1057	,	_	_	
5-23	1058-1066	reducing	_	_	
5-24	1067-1070	the	_	_	
5-25	1071-1079	severity	_	_	
5-26	1080-1082	of	_	_	
5-27	1083-1093	thrombosis	_	_	
5-28	1093-1094	,	_	_	
5-29	1095-1097	or	_	_	
5-30	1098-1107	improving	_	_	
5-31	1108-1111	the	_	_	
5-32	1112-1126	anti-rejection	_	_	
5-33	1127-1137	properties	_	_	
5-34	1138-1140	of	_	_	
5-35	1141-1144	the	_	_	
5-36	1145-1152	medical	_	_	
5-37	1153-1159	device	_	_	
5-38	1159-1160	.	_	_	

#Text=Also provided by this disclosure are methods of imparting antibacterial and/or antithrombogenic properties to a medical device that contains a polyorganosiloxane, the method comprising adding to the polyorganosiloxane or combining with the polyorganosiloxane at least one polyphosphazene of the present invention.
#Text=[0115] Referring to FIGS. 1 through 3, a series of scanning electron microscope (SEM) images are shown that illustrate one manner by which the present invention can impart more biocompatible properties to a device.
6-1	1161-1165	Also	_	_	
6-2	1166-1174	provided	_	_	
6-3	1175-1177	by	_	_	
6-4	1178-1182	this	_	_	
6-5	1183-1193	disclosure	_	_	
6-6	1194-1197	are	_	_	
6-7	1198-1205	methods	_	_	
6-8	1206-1208	of	_	_	
6-9	1209-1218	imparting	_	_	
6-10	1219-1232	antibacterial	_	_	
6-11	1233-1236	and	_	_	
6-12	1236-1237	/	_	_	
6-13	1237-1239	or	_	_	
6-14	1240-1256	antithrombogenic	_	_	
6-15	1257-1267	properties	_	_	
6-16	1268-1270	to	_	_	
6-17	1271-1272	a	_	_	
6-18	1273-1280	medical	_	_	
6-19	1281-1287	device	_	_	
6-20	1288-1292	that	_	_	
6-21	1293-1301	contains	_	_	
6-22	1302-1303	a	_	_	
6-23	1304-1322	polyorganosiloxane	_	_	
6-24	1322-1323	,	_	_	
6-25	1324-1327	the	_	_	
6-26	1328-1334	method	_	_	
6-27	1335-1345	comprising	_	_	
6-28	1346-1352	adding	_	_	
6-29	1353-1355	to	_	_	
6-30	1356-1359	the	_	_	
6-31	1360-1378	polyorganosiloxane	_	_	
6-32	1379-1381	or	_	_	
6-33	1382-1391	combining	_	_	
6-34	1392-1396	with	_	_	
6-35	1397-1400	the	_	_	
6-36	1401-1419	polyorganosiloxane	_	_	
6-37	1420-1422	at	_	_	
6-38	1423-1428	least	_	_	
6-39	1429-1432	one	_	_	
6-40	1433-1448	polyphosphazene	_	_	
6-41	1449-1451	of	_	_	
6-42	1452-1455	the	_	_	
6-43	1456-1463	present	_	_	
6-44	1464-1473	invention	_	_	
6-45	1473-1474	.	_	_	
6-46	1475-1476	[	_	_	
6-47	1476-1480	0115	_	_	
6-48	1480-1481	]	_	_	
6-49	1482-1491	Referring	_	_	
6-50	1492-1494	to	_	_	
6-51	1495-1499	FIGS	_	_	
6-52	1499-1500	.	_	_	
6-53	1501-1502	1	_	_	
6-54	1503-1510	through	_	_	
6-55	1511-1512	3	_	_	
6-56	1512-1513	,	_	_	
6-57	1514-1515	a	_	_	
6-58	1516-1522	series	_	_	
6-59	1523-1525	of	_	_	
6-60	1526-1534	scanning	_	_	
6-61	1535-1543	electron	_	_	
6-62	1544-1554	microscope	_	_	
6-63	1555-1556	(	_	_	
6-64	1556-1559	SEM	_	_	
6-65	1559-1560	)	_	_	
6-66	1561-1567	images	_	_	
6-67	1568-1571	are	_	_	
6-68	1572-1577	shown	_	_	
6-69	1578-1582	that	_	_	
6-70	1583-1593	illustrate	_	_	
6-71	1594-1597	one	_	_	
6-72	1598-1604	manner	_	_	
6-73	1605-1607	by	_	_	
6-74	1608-1613	which	_	_	
6-75	1614-1617	the	_	_	
6-76	1618-1625	present	_	_	
6-77	1626-1635	invention	_	_	
6-78	1636-1639	can	_	_	
6-79	1640-1646	impart	_	_	
6-80	1647-1651	more	_	_	
6-81	1652-1665	biocompatible	_	_	
6-82	1666-1676	properties	_	_	
6-83	1677-1679	to	_	_	
6-84	1680-1681	a	_	_	
6-85	1682-1688	device	_	_	
6-86	1688-1689	.	_	_	

#Text=FIGS. 1 through 3 are images of a surface of a Silastic.RTM.
7-1	1690-1694	FIGS	_	_	
7-2	1694-1695	.	_	_	
7-3	1696-1697	1	_	_	
7-4	1698-1705	through	_	_	
7-5	1706-1707	3	_	_	
7-6	1708-1711	are	_	_	
7-7	1712-1718	images	_	_	
7-8	1719-1721	of	_	_	
7-9	1722-1723	a	_	_	
7-10	1724-1731	surface	_	_	
7-11	1732-1734	of	_	_	
7-12	1735-1736	a	_	_	
7-13	1737-1749	Silastic.RTM	_	_	
7-14	1749-1750	.	_	_	

#Text=Foley catheter that were taken after a 3-day incubation in artificial urine containing E. coli.
8-1	1751-1756	Foley	_	_	
8-2	1757-1765	catheter	_	_	
8-3	1766-1770	that	_	_	
8-4	1771-1775	were	_	_	
8-5	1776-1781	taken	_	_	
8-6	1782-1787	after	_	_	
8-7	1788-1789	a	_	_	
8-8	1790-1791	3	_	_	
8-9	1791-1792	-	_	_	
8-10	1792-1795	day	_	_	
8-11	1796-1806	incubation	_	_	
8-12	1807-1809	in	_	_	
8-13	1810-1820	artificial	_	_	
8-14	1821-1826	urine	_	_	
8-15	1827-1837	containing	_	_	
8-16	1838-1839	E	_	_	
8-17	1839-1840	.	_	_	
8-18	1841-1845	coli	_	_	
8-19	1845-1846	.	_	_	

#Text=In FIG. 1 (1600.times.), the Silastic.RTM.
9-1	1847-1849	In	_	_	
9-2	1850-1853	FIG	_	_	
9-3	1853-1854	.	_	_	
9-4	1855-1856	1	_	_	
9-5	1857-1858	(	_	_	
9-6	1858-1862	1600	_	_	
9-7	1862-1863	.	_	_	
9-8	1863-1868	times	_	_	
9-9	1868-1869	.	_	_	
9-10	1869-1870	)	_	_	
9-11	1870-1871	,	_	_	
9-12	1872-1875	the	_	_	
9-13	1876-1888	Silastic.RTM	_	_	
9-14	1888-1889	.	_	_	

#Text=Foley catheter was treated with poly[bis(2,2,2-trifluoroethoxy)]phosphazene according to this disclosure, and then subjected to the 3-day incubation period.
10-1	1890-1895	Foley	_	_	
10-2	1896-1904	catheter	_	_	
10-3	1905-1908	was	_	_	
10-4	1909-1916	treated	_	_	
10-5	1917-1921	with	_	_	
10-6	1922-1926	poly	_	_	
10-7	1926-1927	[	_	_	
10-8	1927-1930	bis	_	_	
10-9	1930-1931	(	_	_	
10-10	1931-1936	2,2,2	_	_	
10-11	1936-1937	-	_	_	
10-12	1937-1952	trifluoroethoxy	_	_	
10-13	1952-1953	)	_	_	
10-14	1953-1954	]	_	_	
10-15	1954-1965	phosphazene	_	_	
10-16	1966-1975	according	_	_	
10-17	1976-1978	to	_	_	
10-18	1979-1983	this	_	_	
10-19	1984-1994	disclosure	_	_	
10-20	1994-1995	,	_	_	
10-21	1996-1999	and	_	_	
10-22	2000-2004	then	_	_	
10-23	2005-2014	subjected	_	_	
10-24	2015-2017	to	_	_	
10-25	2018-2021	the	_	_	
10-26	2022-2023	3	_	_	
10-27	2023-2024	-	_	_	
10-28	2024-2027	day	_	_	
10-29	2028-2038	incubation	_	_	
10-30	2039-2045	period	_	_	
10-31	2045-2046	.	_	_	

#Text=In FIG. 2 (550.times.) and FIG. 3 (1600.times.), the Silastic.RTM.
11-1	2047-2049	In	_	_	
11-2	2050-2053	FIG	_	_	
11-3	2053-2054	.	_	_	
11-4	2055-2056	2	_	_	
11-5	2057-2058	(	_	_	
11-6	2058-2061	550	_	_	
11-7	2061-2062	.	_	_	
11-8	2062-2067	times	_	_	
11-9	2067-2068	.	_	_	
11-10	2068-2069	)	_	_	
11-11	2070-2073	and	_	_	
11-12	2074-2077	FIG	_	_	
11-13	2077-2078	.	_	_	
11-14	2079-2080	3	_	_	
11-15	2081-2082	(	_	_	
11-16	2082-2086	1600	_	_	
11-17	2086-2087	.	_	_	
11-18	2087-2092	times	_	_	
11-19	2092-2093	.	_	_	
11-20	2093-2094	)	_	_	
11-21	2094-2095	,	_	_	
11-22	2096-2099	the	_	_	
11-23	2100-2112	Silastic.RTM	_	_	
11-24	2112-2113	.	_	_	

#Text=Foley catheter was not treated with any polyphosphazene, and then was subjected to the 3-day incubation period.
12-1	2114-2119	Foley	_	_	
12-2	2120-2128	catheter	_	_	
12-3	2129-2132	was	_	_	
12-4	2133-2136	not	_	_	
12-5	2137-2144	treated	_	_	
12-6	2145-2149	with	_	_	
12-7	2150-2153	any	_	_	
12-8	2154-2169	polyphosphazene	_	_	
12-9	2169-2170	,	_	_	
12-10	2171-2174	and	_	_	
12-11	2175-2179	then	_	_	
12-12	2180-2183	was	_	_	
12-13	2184-2193	subjected	_	_	
12-14	2194-2196	to	_	_	
12-15	2197-2200	the	_	_	
12-16	2201-2202	3	_	_	
12-17	2202-2203	-	_	_	
12-18	2203-2206	day	_	_	
12-19	2207-2217	incubation	_	_	
12-20	2218-2224	period	_	_	
12-21	2224-2225	.	_	_	

#Text=As these SEM data illustrate, no significant calcification or mineralization of the polyphosphazene-treated Silastic.RTM. catheter was observed at the end of the 3-day incubation period (FIG. 1), whereas the untreated Silastic.RTM. catheters exhibited significant calcification after the 3-day incubation period (FIGS. 2 and 3).
13-1	2226-2228	As	_	_	
13-2	2229-2234	these	_	_	
13-3	2235-2238	SEM	_	_	
13-4	2239-2243	data	_	_	
13-5	2244-2254	illustrate	_	_	
13-6	2254-2255	,	_	_	
13-7	2256-2258	no	_	_	
13-8	2259-2270	significant	_	_	
13-9	2271-2284	calcification	_	_	
13-10	2285-2287	or	_	_	
13-11	2288-2302	mineralization	_	_	
13-12	2303-2305	of	_	_	
13-13	2306-2309	the	_	_	
13-14	2310-2333	polyphosphazene-treated	_	_	
13-15	2334-2346	Silastic.RTM	_	_	
13-16	2346-2347	.	_	_	
13-17	2348-2356	catheter	_	_	
13-18	2357-2360	was	_	_	
13-19	2361-2369	observed	_	_	
13-20	2370-2372	at	_	_	
13-21	2373-2376	the	_	_	
13-22	2377-2380	end	_	_	
13-23	2381-2383	of	_	_	
13-24	2384-2387	the	_	_	
13-25	2388-2389	3	_	_	
13-26	2389-2390	-	_	_	
13-27	2390-2393	day	_	_	
13-28	2394-2404	incubation	_	_	
13-29	2405-2411	period	_	_	
13-30	2412-2413	(	_	_	
13-31	2413-2416	FIG	_	_	
13-32	2416-2417	.	_	_	
13-33	2418-2419	1	_	_	
13-34	2419-2420	)	_	_	
13-35	2420-2421	,	_	_	
13-36	2422-2429	whereas	_	_	
13-37	2430-2433	the	_	_	
13-38	2434-2443	untreated	_	_	
13-39	2444-2456	Silastic.RTM	_	_	
13-40	2456-2457	.	_	_	
13-41	2458-2467	catheters	_	_	
13-42	2468-2477	exhibited	_	_	
13-43	2478-2489	significant	_	_	
13-44	2490-2503	calcification	_	_	
13-45	2504-2509	after	_	_	
13-46	2510-2513	the	_	_	
13-47	2514-2515	3	_	_	
13-48	2515-2516	-	_	_	
13-49	2516-2519	day	_	_	
13-50	2520-2530	incubation	_	_	
13-51	2531-2537	period	_	_	
13-52	2538-2539	(	_	_	
13-53	2539-2543	FIGS	_	_	
13-54	2543-2544	.	_	_	
13-55	2545-2546	2	_	_	
13-56	2547-2550	and	_	_	
13-57	2551-2552	3	_	_	
13-58	2552-2553	)	_	_	
13-59	2553-2554	.	_	_	

#Text=Thus, the FIGS. 2 and 3 samples clearly show more crystal formation, where the mineral deposits appear as the needle-shaped material.
14-1	2555-2559	Thus	_	_	
14-2	2559-2560	,	_	_	
14-3	2561-2564	the	_	_	
14-4	2565-2569	FIGS	_	_	
14-5	2569-2570	.	_	_	
14-6	2571-2572	2	_	_	
14-7	2573-2576	and	_	_	
14-8	2577-2578	3	_	_	
14-9	2579-2586	samples	_	_	
14-10	2587-2594	clearly	_	_	
14-11	2595-2599	show	_	_	
14-12	2600-2604	more	_	_	
14-13	2605-2612	crystal	_	_	
14-14	2613-2622	formation	_	_	
14-15	2622-2623	,	_	_	
14-16	2624-2629	where	_	_	
14-17	2630-2633	the	_	_	
14-18	2634-2641	mineral	_	_	
14-19	2642-2650	deposits	_	_	
14-20	2651-2657	appear	_	_	
14-21	2658-2660	as	_	_	
14-22	2661-2664	the	_	_	
14-23	2665-2678	needle-shaped	_	_	
14-24	2679-2687	material	_	_	
14-25	2687-2688	.	_	_	

#Text=Therefore, in still another aspect, the present disclosure also provides a method of reducing calcification of a polyorganosiloxane-containing device that has contact with tissue or fluids of the human or animal body or organ, comprising adding a polyphosphazene to the polyorganosiloxane.
15-1	2689-2698	Therefore	_	_	
15-2	2698-2699	,	_	_	
15-3	2700-2702	in	_	_	
15-4	2703-2708	still	_	_	
15-5	2709-2716	another	_	_	
15-6	2717-2723	aspect	_	_	
15-7	2723-2724	,	_	_	
15-8	2725-2728	the	_	_	
15-9	2729-2736	present	_	_	
15-10	2737-2747	disclosure	_	_	
15-11	2748-2752	also	_	_	
15-12	2753-2761	provides	_	_	
15-13	2762-2763	a	*[1]	16-5[2_1]	
15-14	2764-2770	method	*[1]	_	
15-15	2771-2773	of	*[1]	_	
15-16	2774-2782	reducing	*[1]	_	
15-17	2783-2796	calcification	*[1]	_	
15-18	2797-2799	of	*[1]	_	
15-19	2800-2801	a	*[1]	_	
15-20	2802-2831	polyorganosiloxane-containing	*[1]	_	
15-21	2832-2838	device	*[1]	_	
15-22	2839-2843	that	*[1]	_	
15-23	2844-2847	has	*[1]	_	
15-24	2848-2855	contact	*[1]	_	
15-25	2856-2860	with	*[1]	_	
15-26	2861-2867	tissue	*[1]	_	
15-27	2868-2870	or	*[1]	_	
15-28	2871-2877	fluids	*[1]	_	
15-29	2878-2880	of	*[1]	_	
15-30	2881-2884	the	*[1]	_	
15-31	2885-2890	human	*[1]	_	
15-32	2891-2893	or	*[1]	_	
15-33	2894-2900	animal	*[1]	_	
15-34	2901-2905	body	*[1]	_	
15-35	2906-2908	or	*[1]	_	
15-36	2909-2914	organ	*[1]	_	
15-37	2914-2915	,	_	_	
15-38	2916-2926	comprising	_	_	
15-39	2927-2933	adding	_	_	
15-40	2934-2935	a	_	_	
15-41	2936-2951	polyphosphazene	_	_	
15-42	2952-2954	to	_	_	
15-43	2955-2958	the	_	_	
15-44	2959-2977	polyorganosiloxane	_	_	
15-45	2977-2978	.	_	_	

#Text=As described herein, this method also is not limited as to the exact disposition of the polyorganosiloxane and polyphosphazene components, for example, the polyorganosiloxane can be coated with, blended with, mixed with, grafted to, bonded to, layered on, or combined with in any manner.
#Text=[0116] In summary, the present disclosure provides methods and devices and related inventions whereby a polyphosphazene is added to a silicone-containing device to provide the device with enhanced and superior properties relative to the device in the absence of the polyphosphazene.
16-1	2979-2981	As	_	_	
16-2	2982-2991	described	_	_	
16-3	2992-2998	herein	_	_	
16-4	2998-2999	,	_	_	
16-5	3000-3004	this	*[2]	_	
16-6	3005-3011	method	*[2]	_	
16-7	3012-3016	also	_	_	
16-8	3017-3019	is	_	_	
16-9	3020-3023	not	_	_	
16-10	3024-3031	limited	_	_	
16-11	3032-3034	as	_	_	
16-12	3035-3037	to	_	_	
16-13	3038-3041	the	_	_	
16-14	3042-3047	exact	_	_	
16-15	3048-3059	disposition	_	_	
16-16	3060-3062	of	_	_	
16-17	3063-3066	the	_	_	
16-18	3067-3085	polyorganosiloxane	_	_	
16-19	3086-3089	and	_	_	
16-20	3090-3105	polyphosphazene	_	_	
16-21	3106-3116	components	_	_	
16-22	3116-3117	,	_	_	
16-23	3118-3121	for	_	_	
16-24	3122-3129	example	_	_	
16-25	3129-3130	,	_	_	
16-26	3131-3134	the	_	_	
16-27	3135-3153	polyorganosiloxane	_	_	
16-28	3154-3157	can	_	_	
16-29	3158-3160	be	_	_	
16-30	3161-3167	coated	_	_	
16-31	3168-3172	with	_	_	
16-32	3172-3173	,	_	_	
16-33	3174-3181	blended	_	_	
16-34	3182-3186	with	_	_	
16-35	3186-3187	,	_	_	
16-36	3188-3193	mixed	_	_	
16-37	3194-3198	with	_	_	
16-38	3198-3199	,	_	_	
16-39	3200-3207	grafted	_	_	
16-40	3208-3210	to	_	_	
16-41	3210-3211	,	_	_	
16-42	3212-3218	bonded	_	_	
16-43	3219-3221	to	_	_	
16-44	3221-3222	,	_	_	
16-45	3223-3230	layered	_	_	
16-46	3231-3233	on	_	_	
16-47	3233-3234	,	_	_	
16-48	3235-3237	or	_	_	
16-49	3238-3246	combined	_	_	
16-50	3247-3251	with	_	_	
16-51	3252-3254	in	_	_	
16-52	3255-3258	any	_	_	
16-53	3259-3265	manner	_	_	
16-54	3265-3266	.	_	_	
16-55	3267-3268	[	_	_	
16-56	3268-3272	0116	_	_	
16-57	3272-3273	]	_	_	
16-58	3274-3276	In	_	_	
16-59	3277-3284	summary	_	_	
16-60	3284-3285	,	_	_	
16-61	3286-3289	the	_	_	
16-62	3290-3297	present	_	_	
16-63	3298-3308	disclosure	_	_	
16-64	3309-3317	provides	_	_	
16-65	3318-3325	methods	_	_	
16-66	3326-3329	and	_	_	
16-67	3330-3337	devices	_	_	
16-68	3338-3341	and	_	_	
16-69	3342-3349	related	_	_	
16-70	3350-3360	inventions	_	_	
16-71	3361-3368	whereby	_	_	
16-72	3369-3370	a	_	_	
16-73	3371-3386	polyphosphazene	_	_	
16-74	3387-3389	is	_	_	
16-75	3390-3395	added	_	_	
16-76	3396-3398	to	_	_	
16-77	3399-3400	a	_	_	
16-78	3401-3420	silicone-containing	_	_	
16-79	3421-3427	device	_	_	
16-80	3428-3430	to	_	_	
16-81	3431-3438	provide	_	_	
16-82	3439-3442	the	_	_	
16-83	3443-3449	device	_	_	
16-84	3450-3454	with	_	_	
16-85	3455-3463	enhanced	_	_	
16-86	3464-3467	and	_	_	
16-87	3468-3476	superior	_	_	
16-88	3477-3487	properties	_	_	
16-89	3488-3496	relative	_	_	
16-90	3497-3499	to	_	_	
16-91	3500-3503	the	_	_	
16-92	3504-3510	device	_	_	
16-93	3511-3513	in	_	_	
16-94	3514-3517	the	_	_	
16-95	3518-3525	absence	_	_	
16-96	3526-3528	of	_	_	
16-97	3529-3532	the	_	_	
16-98	3533-3548	polyphosphazene	_	_	
16-99	3548-3549	.	_	_	

#Text=In particular, the silicone-polyphosphazene device has enhanced antibacterial properties, antithrombogenic properties, enhanced flow characteristics, enhanced lubricity, enhanced biocompatibility properties, enhanced resistance to degradation, and anti-rejection properties.
#Text=[0117] The present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof.
17-1	3550-3552	In	_	_	
17-2	3553-3563	particular	_	_	
17-3	3563-3564	,	_	_	
17-4	3565-3568	the	_	_	
17-5	3569-3593	silicone-polyphosphazene	_	_	
17-6	3594-3600	device	_	_	
17-7	3601-3604	has	_	_	
17-8	3605-3613	enhanced	_	_	
17-9	3614-3627	antibacterial	_	_	
17-10	3628-3638	properties	_	_	
17-11	3638-3639	,	_	_	
17-12	3640-3656	antithrombogenic	_	_	
17-13	3657-3667	properties	_	_	
17-14	3667-3668	,	_	_	
17-15	3669-3677	enhanced	_	_	
17-16	3678-3682	flow	_	_	
17-17	3683-3698	characteristics	_	_	
17-18	3698-3699	,	_	_	
17-19	3700-3708	enhanced	_	_	
17-20	3709-3718	lubricity	_	_	
17-21	3718-3719	,	_	_	
17-22	3720-3728	enhanced	_	_	
17-23	3729-3745	biocompatibility	_	_	
17-24	3746-3756	properties	_	_	
17-25	3756-3757	,	_	_	
17-26	3758-3766	enhanced	_	_	
17-27	3767-3777	resistance	_	_	
17-28	3778-3780	to	_	_	
17-29	3781-3792	degradation	_	_	
17-30	3792-3793	,	_	_	
17-31	3794-3797	and	_	_	
17-32	3798-3812	anti-rejection	_	_	
17-33	3813-3823	properties	_	_	
17-34	3823-3824	.	_	_	
17-35	3825-3826	[	_	_	
17-36	3826-3830	0117	_	_	
17-37	3830-3831	]	_	_	
17-38	3832-3835	The	_	_	
17-39	3836-3843	present	_	_	
17-40	3844-3853	invention	_	_	
17-41	3854-3856	is	_	_	
17-42	3857-3864	further	_	_	
17-43	3865-3876	illustrated	_	_	
17-44	3877-3879	by	_	_	
17-45	3880-3883	the	_	_	
17-46	3884-3893	following	_	_	
17-47	3894-3902	examples	_	_	
17-48	3902-3903	,	_	_	
17-49	3904-3909	which	_	_	
17-50	3910-3913	are	_	_	
17-51	3914-3917	not	_	_	
17-52	3918-3920	to	_	_	
17-53	3921-3923	be	_	_	
17-54	3924-3933	construed	_	_	
17-55	3934-3936	in	_	_	
17-56	3937-3940	any	_	_	
17-57	3941-3944	way	_	_	
17-58	3945-3947	as	_	_	
17-59	3948-3956	imposing	_	_	
17-60	3957-3968	limitations	_	_	
17-61	3969-3973	upon	_	_	
17-62	3974-3977	the	_	_	
17-63	3978-3983	scope	_	_	
17-64	3984-3991	thereof	_	_	
17-65	3991-3992	.	_	_	

#Text=On the contrary, it is to be clearly understood that resort can be had to various other aspects, embodiments, modifications, and equivalents thereof which, after reading the description herein, can suggest themselves to one of ordinary skill in the art without departing from the spirit of the present invention or the scope of the appended claims.
18-1	3993-3995	On	_	_	
18-2	3996-3999	the	_	_	
18-3	4000-4008	contrary	_	_	
18-4	4008-4009	,	_	_	
18-5	4010-4012	it	_	_	
18-6	4013-4015	is	_	_	
18-7	4016-4018	to	_	_	
18-8	4019-4021	be	_	_	
18-9	4022-4029	clearly	_	_	
18-10	4030-4040	understood	_	_	
18-11	4041-4045	that	_	_	
18-12	4046-4052	resort	_	_	
18-13	4053-4056	can	_	_	
18-14	4057-4059	be	_	_	
18-15	4060-4063	had	_	_	
18-16	4064-4066	to	_	_	
18-17	4067-4074	various	_	_	
18-18	4075-4080	other	_	_	
18-19	4081-4088	aspects	_	_	
18-20	4088-4089	,	_	_	
18-21	4090-4101	embodiments	_	_	
18-22	4101-4102	,	_	_	
18-23	4103-4116	modifications	_	_	
18-24	4116-4117	,	_	_	
18-25	4118-4121	and	_	_	
18-26	4122-4133	equivalents	_	_	
18-27	4134-4141	thereof	_	_	
18-28	4142-4147	which	_	_	
18-29	4147-4148	,	_	_	
18-30	4149-4154	after	_	_	
18-31	4155-4162	reading	_	_	
18-32	4163-4166	the	_	_	
18-33	4167-4178	description	_	_	
18-34	4179-4185	herein	_	_	
18-35	4185-4186	,	_	_	
18-36	4187-4190	can	_	_	
18-37	4191-4198	suggest	_	_	
18-38	4199-4209	themselves	_	_	
18-39	4210-4212	to	_	_	
18-40	4213-4216	one	_	_	
18-41	4217-4219	of	_	_	
18-42	4220-4228	ordinary	_	_	
18-43	4229-4234	skill	_	_	
18-44	4235-4237	in	_	_	
18-45	4238-4241	the	_	_	
18-46	4242-4245	art	_	_	
18-47	4246-4253	without	_	_	
18-48	4254-4263	departing	_	_	
18-49	4264-4268	from	_	_	
18-50	4269-4272	the	_	_	
18-51	4273-4279	spirit	_	_	
18-52	4280-4282	of	_	_	
18-53	4283-4286	the	_	_	
18-54	4287-4294	present	_	_	
18-55	4295-4304	invention	_	_	
18-56	4305-4307	or	_	_	
18-57	4308-4311	the	_	_	
18-58	4312-4317	scope	_	_	
18-59	4318-4320	of	_	_	
18-60	4321-4324	the	_	_	
18-61	4325-4333	appended	_	_	
18-62	4334-4340	claims	_	_	
18-63	4340-4341	.	_	_	
